This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany



Adrenomed is a precision medicine company specialized in preserving vascular integrity in life-threatening conditions. We have conducted a successful phase 2 trial in septic shock and are now planning a global pivotal trial. 

The company’s lead candidate Adrecizumab is a clinical stage, first-in-class monoclonal antibody that targets the vasoprotective peptide Adrenomedullin (ADM), to treat conditions associated with increased  endothelial barrier dysfunction, vascular leakage,and shock. 

The company’s biomarker-guided approach allows to identify patients suffering from the targeted pathophysiology of endothelial barrier dysfunction (inclusion/bio-ADM) and to exclude non-addressable pathways (DPP3), thereby greatly mitigating development risks.

We're bringing you

  • Company Presentations